These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 15252316)
21. E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast. Gupta D; Croitoru CM; Ayala AG; Sahin AA; Middleton LP Ann Diagn Pathol; 2002 Jun; 6(3):141-7. PubMed ID: 12089723 [TBL] [Abstract][Full Text] [Related]
22. Expression of c-kit in common benign and malignant breast lesions. Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P Tumori; 2010; 96(6):978-84. PubMed ID: 21388062 [TBL] [Abstract][Full Text] [Related]
23. E-cadherin immunohistochemistry in breast pathology: uses and pitfalls. Canas-Marques R; Schnitt SJ Histopathology; 2016 Jan; 68(1):57-69. PubMed ID: 26768029 [TBL] [Abstract][Full Text] [Related]
24. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions. MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S; Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281 [TBL] [Abstract][Full Text] [Related]
25. E-cadherin expression correlates with histologic type but not tumour grade in invasive breast cancer. Nurismah MI; Noriah O; Suryati MY; Sharifah NA Asian Pac J Cancer Prev; 2008; 9(4):699-702. PubMed ID: 19256762 [TBL] [Abstract][Full Text] [Related]
26. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions. Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376 [TBL] [Abstract][Full Text] [Related]
28. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Kovács A; Dhillon J; Walker RA Mol Pathol; 2003 Dec; 56(6):318-22. PubMed ID: 14645693 [TBL] [Abstract][Full Text] [Related]
29. Cytokeratin intermediate filament expression in benign and malignant breast disease. Heatley M; Maxwell P; Whiteside C; Toner P J Clin Pathol; 1995 Jan; 48(1):26-32. PubMed ID: 7535804 [TBL] [Abstract][Full Text] [Related]
30. Significance of Matrix Metalloproteinase 9 Expression as Supporting Marker to Cytokeratin 19 mRNA in Sentinel Lymph Nodes in Breast Cancer Patients. Murawski M; Woźniak M; Duś-Szachniewicz K; Kołodziej P; Rzeszutko M; Ziółkowski P Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110764 [TBL] [Abstract][Full Text] [Related]
31. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. O'Malley FP; Saad Z; Kerkvliet N; Doig G; Stitt L; Ainsworth P; Hundal H; Chambers AF; Turnbull DI; Bramwell V Hum Pathol; 1996 Sep; 27(9):955-63. PubMed ID: 8816892 [TBL] [Abstract][Full Text] [Related]
32. Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Wheeler DT; Tai LH; Bratthauer GL; Waldner DL; Tavassoli FA Am J Surg Pathol; 2004 Dec; 28(12):1587-93. PubMed ID: 15577677 [TBL] [Abstract][Full Text] [Related]
33. [Matrix-producing breast carcinoma with myoepithelial differentiation--description of 11 cases and review of literature aimed at histogenesis and differential diagnosis]. Kinkor Z; Boudová L; Ryska A; Kajo K; Svec A Ceska Gynekol; 2004 May; 69(3):229-36. PubMed ID: 15310000 [TBL] [Abstract][Full Text] [Related]
34. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Clezardin P; Frappart L; Clerget M; Pechoux C; Delmas PD Cancer Res; 1993 Mar; 53(6):1421-30. PubMed ID: 7680285 [TBL] [Abstract][Full Text] [Related]
35. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia. Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808 [TBL] [Abstract][Full Text] [Related]
36. [Detection of lymph nodes micrometastases in breast carcinoma using immunohistochemistry for cytokeratin 8]. Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E Rev Med Chir Soc Med Nat Iasi; 2002; 106(4):720-4. PubMed ID: 14974217 [TBL] [Abstract][Full Text] [Related]
37. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells. Rohilla M; Bal A; Singh G; Joshi K Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939 [TBL] [Abstract][Full Text] [Related]
38. SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue. Chiu K; Ionescu DN; Hayes M Virchows Arch; 2019 Jun; 474(6):667-672. PubMed ID: 30903273 [TBL] [Abstract][Full Text] [Related]
39. Morphologic, molecular and microenvironment factors associated with stromal invasion in breast ductal carcinoma in situ: Role of myoepithelial cells. Aguiar FN; Cirqueira CS; Bacchi CE; Carvalho FM Breast Dis; 2015; 35(4):249-52. PubMed ID: 26397772 [TBL] [Abstract][Full Text] [Related]
40. Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast. Afify A; McNiel MA; Braggin J; Bailey H; Paulino AF Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):121-7. PubMed ID: 18227732 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]